2021
Behavioral counseling and abstinence‐contingent take‐home buprenorphine in general practitioners’ offices in Malaysia: a randomized, open‐label clinical trial
Schottenfeld RS, Chawarski M, Mazlan M. Behavioral counseling and abstinence‐contingent take‐home buprenorphine in general practitioners’ offices in Malaysia: a randomized, open‐label clinical trial. Addiction 2021, 116: 2135-2149. PMID: 33404150, DOI: 10.1111/add.15399.Peer-Reviewed Original ResearchConceptsOpioid-negative urine testsBuprenorphine-naloxone treatmentBehavioral counselingPhysician managementBehavioral interventionsUrine testsClinical trialsOpen-label clinical trialTake-home dosesOpioid-dependent patientsWeeks of treatmentOpioid use disorderPrimary care physiciansOpioid-dependent individualsHIV risk behaviorsGeneral practitioner's officeBuprenorphine-naloxoneOpioid usePrimary outcomeCare physiciansTreatment outcomesStudy interventionTreatment accessTreatment groupsUse disorders
2020
Use of Amphetamine-Type Stimulants Among Emergency Department Patients With Untreated Opioid Use Disorder
Chawarski MC, Hawk K, Edelman EJ, O'Connor P, Owens P, Martel S, Coupet E, Whiteside L, Tsui JI, Rothman R, Cowan E, Richardson L, Lyons MS, Fiellin DA, D'Onofrio G. Use of Amphetamine-Type Stimulants Among Emergency Department Patients With Untreated Opioid Use Disorder. Annals Of Emergency Medicine 2020, 76: 782-787. PMID: 32782084, PMCID: PMC8048036, DOI: 10.1016/j.annemergmed.2020.06.046.Peer-Reviewed Original ResearchConceptsUntreated opioid use disorderOpioid use disorderAmphetamine-type stimulant useUse disordersStimulant useAmphetamine-type stimulantsStudy admissionEmergency departmentEmergency department patientsImplementation science studyUrine test resultsFalse discovery rate correctionSubstance use problemsHepatitis CED visitsDepartment patientsReferral protocolsED patientsUrine testsDrug injectionOverdose riskPatientsHealth factorsUnstable housingConcurrent use
2018
Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial
Schottenfeld RS, Chawarski MC, Sofuoglu M, Chooi WT, Zaharim NM, M Yasin MA, Ahmad I, Syed Jaapar SZ, Vicknasingam BK. Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial. Drug And Alcohol Dependence 2018, 186: 130-137. PMID: 29573648, PMCID: PMC5911201, DOI: 10.1016/j.drugalcdep.2018.01.017.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAdultAmphetamine-Related DisordersAtomoxetine HydrochlorideBehavior TherapyBuprenorphineBuprenorphine, Naloxone Drug CombinationDepressionDouble-Blind MethodHumansMaleMiddle AgedNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsTreatment OutcomeYoung AdultConceptsATS use disorderPlacebo-treated participantsUse disordersAdverse eventsUrine testsPotential efficacyAmphetamine-type stimulant dependenceAmphetamine-type stimulant useSerious adverse eventsBuprenorphine/naloxoneBetween-group differencesATS dependenceClinical tolerabilityMedication discontinuationBuprenorphine treatmentPrimary outcomeOpioid dependenceClinical trialsITT sampleTreat sampleBehavioral counselingDepressive symptomsDays abstinentAtomoxetineStimulant dependence
2016
Medical treatments for opioid use disorder in Iran: a randomized, double‐blind placebo‐controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment
Mokri A, Chawarski MC, Taherinakhost H, Schottenfeld RS. Medical treatments for opioid use disorder in Iran: a randomized, double‐blind placebo‐controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment. Addiction 2016, 111: 874-882. PMID: 26639678, DOI: 10.1111/add.13259.Peer-Reviewed Original ResearchConceptsOpioid-negative urine testsBuprenorphine/naloxoneOpioid use disorderSublingual buprenorphine/naloxoneUrine testsUse disordersOral naltrexoneOpioid abstinenceClinical trialsTreatment retentionDouble-blind placebo-controlled comparisonMean numberDouble-blind clinical trialOpioid use disorder treatmentNaltrexone maintenance treatmentTwo-group parallelEffective opioid use disorder treatmentPlacebo-controlled comparisonUrine toxicology testsPilot clinical trialGroup drug counselingUse disorder treatmentClinical research programBNx groupNTX group
2015
Evaluation of an implementation of methadone maintenance treatment in China
Marienfeld C, Liu P, Wang X, Schottenfeld R, Zhou W, Chawarski MC. Evaluation of an implementation of methadone maintenance treatment in China. Drug And Alcohol Dependence 2015, 157: 60-67. PMID: 26601934, PMCID: PMC4663107, DOI: 10.1016/j.drugalcdep.2015.10.001.Peer-Reviewed Original ResearchConceptsInjection drug useMethadone maintenance treatmentMMT exposureDrug useMaintenance treatmentUrine testsPositive testOpiate positive urine testsDaily methadone dosesPositive urine testHigher adherence ratesOpioid use disorderNegative urine testsSelf-reported drug useElectronic medical recordsPriority improvement areasMonth drug useMethadone dosesMethadone dosingDose adjustmentAdherence ratesDaily dosesMedical recordsTreatment daysUse disordersBuprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients
Vicknasingam B, Dazali MN, Singh D, Schottenfeld RS, Chawarski MC. Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients. Drug And Alcohol Dependence 2015, 152: 164-169. PMID: 25935736, DOI: 10.1016/j.drugalcdep.2015.04.007.Peer-Reviewed Original ResearchConceptsBUP/NXNX treatmentGeneral practitionersPast monthOpiate positive urine testsOptimal treatment effectivenessRoutine toxicology testingToxicology testingBuprenorphine/naloxonePositive urine testUrine toxicology testingIllicit opiate useInjection of heroinInjection of drugsCross-sectional surveyMaintenance treatmentPatient surveyUrine testingUrine testsTreatment responseOpiate usePatient experiencePatientsDispensing practicesDrug useHepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China
Zhou W, Wang X, Zhou S, Xie N, Liu P, Luo L, Peng J, Liu M, Desrosiers A, Schottenfeld R, Chawarski MC. Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China. Addiction 2015, 110: 796-802. PMID: 25529103, PMCID: PMC4598328, DOI: 10.1111/add.12836.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentInjection drug useHCV seroconversionPatients HCVSeroconversion ratesDrug useOpiate positive urine testsHepatitis C virus infectionRisk behaviorsMethadone maintenance treatment patientsMethadone maintenance treatment programHepatitis C seroconversionC virus infectionUrine toxicology resultsHepatitis C virusMaintenance treatment programPotential risk factorsOpiate-dependent individualsCross-sectional surveyHCV seroprevalenceMMT clinicsMaintenance treatmentTreatment patientsC virusUrine tests
2013
Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment
Schottenfeld RS, Chawarski MC, Cubells JF, George TP, Lappalainen J, Kosten TR. Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug And Alcohol Dependence 2013, 136: 36-42. PMID: 24462581, DOI: 10.1016/j.drugalcdep.2013.12.007.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlcohol DeterrentsAlcoholismAllelesBuprenorphineCocaine-Related DisordersData Interpretation, StatisticalDisulfiramDNADouble-Blind MethodDrug Therapy, CombinationFemaleGenotypeHumansMaleMiddle AgedNarcotic AntagonistsOpioid-Related DisordersPharmacogeneticsPolymerase Chain ReactionSample SizeTreatment OutcomeYoung AdultConceptsUrine testsCocaine useMechanism of actionCocaine dependenceClinical trialsWeeks abstinencePlacebo-controlled clinical trialEfficacy of disulfiramPharmacogenetics of responseDouble-blind treatmentBuprenorphine maintenance treatmentRandomized clinical trialsOpioid-dependent participantsT allele carriersFrequent cocaine useDopamine β-hydroxylaseBuprenorphine treatmentPrimary outcomeTreat comparisonMaintenance treatmentPharmacogenetic interactionsTreatment responseTT genotypeCocaine abstinenceConsecutive weeks
2007
Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial
Chawarski MC, Mazlan M, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial. Drug And Alcohol Dependence 2007, 94: 281-284. PMID: 18164145, DOI: 10.1016/j.drugalcdep.2007.11.008.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance treatmentOpioid-negative urine testsHIV risk reduction counselingRisk reduction counselingHIV risk behaviorsBehavioral drugReduction counselingUrine testsClinical trialsDrug counselingRisk behaviorsSelf-reported HIV risk behaviorsTake-home dosesUrine toxicology testsHeroin-dependent individualsIndividual drug counselingSelf-reported drug useMaintenance treatmentMedication adherenceLimited counselingBuprenorphineDrug useConsecutive abstinenceToxicology testsOverall proportion
2005
Methadone Versus Buprenorphine With Contingency Management or Performance Feedback for Cocaine and Opioid Dependence
Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR. Methadone Versus Buprenorphine With Contingency Management or Performance Feedback for Cocaine and Opioid Dependence. American Journal Of Psychiatry 2005, 162: 340-349. PMID: 15677600, DOI: 10.1176/appi.ajp.162.2.340.Peer-Reviewed Original ResearchConceptsCo-occurring cocaineDrug-free testOpioid dependenceMaintenance treatmentContingency managementOpioid agonist maintenance treatmentAgonist maintenance treatmentDaily sublingual buprenorphineEffects of buprenorphinePrimary outcome measureMixed-model repeated-measures analysisDouble-blind designUrine test resultsNarcotic treatment programsVoucher valueRepeated-measures analysisSublingual buprenorphineTreatment guidelinesIllicit opioidsUrine testsTreatment outcomesOutcome measuresSustained abstinenceWeek 13Buprenorphine
2000
Thrice-weekly versus daily buprenorphine maintenance
Schottenfeld R, Pakes J, O’Connor P, Chawarski M, Oliveto A, Kosten T. Thrice-weekly versus daily buprenorphine maintenance. Biological Psychiatry 2000, 47: 1072-1079. PMID: 10862807, DOI: 10.1016/s0006-3223(99)00270-x.Peer-Reviewed Original ResearchConceptsSublingual buprenorphineMaintenance treatmentSelf-reported illicit drug useDrug useOpioid agonist maintenance treatmentOpioid-positive urine testsAgonist maintenance treatmentDaily clinic attendanceDaily sublingual buprenorphineThrice-weekly dosingOpioid-dependent patientsUrine toxicology testsSignificant differencesIllicit drug useSelf-reported numberBuprenorphine maintenanceClinic attendanceWeekly doseIllicit opioidsMedication complianceThrice weeklyUrine testsOutcome measuresBuprenorphineCounseling attendanceDisulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial
George T, Chawarski M, Pakes J, Carroll K, Kosten T, Schottenfeld R. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biological Psychiatry 2000, 47: 1080-1086. PMID: 10862808, DOI: 10.1016/s0006-3223(99)00310-8.Peer-Reviewed Original ResearchConceptsBuprenorphine-maintained subjectsCocaine dependenceUrine testsBuprenorphine-maintained patientsEffect of disulfiramContinuous cocaine abstinenceCocaine-dependent subjectsDrug use severityBuprenorphine maintenancePlacebo treatmentDisulfiram groupPlaceboCocaine abstinencePotential efficacyDependent subjectsBaseline measuresDisulfiramNumber of daysWeeksHigh rateSubjectsTrialsPreliminary trialTreatmentPreliminary study